Man Group’s Immunome IMNM Stock Holding History

Man Group’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,614	Closed	-$192K	–	2333
2025 Q2	$192K	Sell	20,614 -1,931	-9%	-$15.8K	﹤0.01%	2080
2025 Q1	$152K	Buy	+22,545	New	+$216K	﹤0.01%	2075
2024 Q2	–	Sell	-44,853	Closed	-$1.11M	–	2130
2024 Q1	$1.11M	Buy	44,853 +21,363	+91%	+$434K	﹤0.01%	1509
2023 Q4	$251K	Buy	+23,490	New	+$195K	﹤0.01%	1861

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Man Group's IMNM Position: Q3 2025 in Review

Man Group sold out of Immunome (IMNM) in Q3 2025, closing a stake of 20,614 shares — an estimated $192K sold.

Man Group first reported a position in IMNM in Q4 2023 and held it in 4 quarters. The position peaked at $1.11M in Q1 2024. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

Man Group reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
Man Group sold 20,614 Immunome shares in Q3 2025, an estimated $192K.
Man Group first reported a position in Immunome in Q4 2023 and held it in 4 quarters.
Man Group's Immunome position peaked at $1.11M in Q1 2024.
153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.